Who are Onabotulinumtoxin A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OnabotulinumtoxinA 100 UNT, OnabotulinumtoxinA 50 UNT [Botox Cosmetic], BOTOX®/VISTABEL®, OnabotulinumtoxinA (ONA), PrabotulinumtoxinA-Xvfs, Xeomin®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/onabotulinumtoxin-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Onabotulinumtoxin A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Onabotulinumtoxin A (Onabotulinumtoxin A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology, Dermatology, Urology.

marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology, Dermatology, Urology Small molecule Live · refreshed every 30 min

Target snapshot

Onabotulinumtoxin A (Onabotulinumtoxin A) — Wake Forest University Health Sciences. Onabotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Onabotulinumtoxin A TARGET	Onabotulinumtoxin A	Wake Forest University Health Sciences	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 100 UNT	OnabotulinumtoxinA 100 UNT	University of South Florida	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 50 UNT [Botox Cosmetic]	OnabotulinumtoxinA 50 UNT [Botox Cosmetic]	Amir Moradi MD, MBA	marketed	Botulinum toxin	SNARE complex (synaptosome-associated protein)
BOTOX®/VISTABEL®	BOTOX®/VISTABEL®	AbbVie	marketed	Botulinum toxin	SNARE complex (synaptosome-associated protein)
OnabotulinumtoxinA (ONA)	OnabotulinumtoxinA (ONA)	Hexsel Dermatology Clinic	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
PrabotulinumtoxinA-Xvfs	PrabotulinumtoxinA-Xvfs	Lupo Center for Aesthetic and General Dermatology	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
Xeomin®	Xeomin®	ATGC Co., Ltd.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery at neuromuscular junction)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

Galderma R&D · 2 drugs in this class
Hexsel Dermatology Clinic · 2 drugs in this class
Seoul National University Hospital · 2 drugs in this class
University of Utah · 2 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
EuBiologics Co.,Ltd · 1 drug in this class
Allergan · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Onabotulinumtoxin A — Competitive Intelligence Brief. https://druglandscape.com/ci/onabotulinumtoxin-a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing